BBIO vs CM: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

CM is the larger of the two ($94.53B market cap): the incumbent the market prices for continued execution (12.86x forward earnings, beta 1.23). BBIO is the smaller challenger ($15.03B), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, BBIO fits: analysts expect its revenue to rise 52% next year, against 5% for CM. If you believe in profit, CM fits: it is expected to make money next year (12.86x forward earnings), while BBIO is still expected to post a loss.

BBIO vs CM: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricBBIOCMWhat it tells you
Market cap$15.03B$94.53BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-282.2512.86Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.941.23Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range47% of range51% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Before you buy: how BBIO and CM affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BBIO and CM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BBIO and CM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does BridgeBio Pharma (BBIO) do?

BridgeBio Pharma (NASDAQ: BBIO) is a Palo Alto-based biopharmaceutical company focused on genetic diseases and genetically driven cancers. Its commercial engine is Attruby (acoramidis), an oral TTR stabilizer approved by the FDA in November 2024 for transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive and often underdiagnosed heart condition. Attruby competes in a market long dominated by Pfizer's tafamidis franchise, and BridgeBio has been rapidly building prescriber and patient uptake since launch.

Full BBIO guide

What does Canadian Imperial Bank of Commerce (CM) do?

Canadian Imperial Bank of Commerce, founded in 1867 and run out of CIBC Square in Toronto, banks roughly 15 million personal, business, public-sector and institutional clients. Reporting today splits into Canadian Personal and Business Banking, Canadian Commercial Banking and Wealth Management, U.S. Commercial Banking and Wealth Management, Capital Markets and Direct Financial Services, plus a Corporate and Other bucket. The balance sheet held ~C$832.8 billion of deposits and ~C$358.4 billion of risk-weighted assets at April 30, 2026, alongside ~C$4.15 trillion of assets under administration and ~C$455 billion under management. Harry Culham became president and chief executive in 2025, and in May 2026 the bank reshuffled its leadership and agreed to sell its 91.67% stake in CIBC Caribbean to Bermuda's Bank of N.T. Butterfield for ~US$1.645 billion, taking US$1 billion in cash and a ~22% equity stake in the buyer. One quirk to keep straight: the fiscal year ends October 31, so quarters are reported on a December, February, May and August cycle.

Full CM guide

BBIO vs CM: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • BBIO drivers: Attruby (acoramidis) commercial ramp; Pipeline diversification and 2026 filings.
  • CM drivers: Margin expansion in the Canadian retail bank; Redeploying capital into the US franchise.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is concentration: Attruby is BridgeBio's only approved commercial product, so near-term performance is highly dependent on a single therapy in a competitive market. For CM, cIBC carries the heaviest relative exposure to Canadian residential mortgages of the country's large banks, and gross impaired loans reached ~C$3,967 million at April 30, 2026, up ~C$672 million from a year earlier, with the loan loss ratio at 0.38%.

BBIO or CM: which should you pick?

If the story you believe is BBIO's (Attruby (acoramidis) commercial ramp), BBIO is the more direct way to own it; if it is CM's (Margin expansion in the Canadian retail bank), CM is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BBIO and CM guides.

BBIO vs CM: the full fundamentals

BBIO. BBIO trades at about 16 times trailing revenue, a multiple that rests on continued Attruby growth and pipeline launches, since the company still loses money. Third-quarter revenue nearly tripled year over year and the loss per share beat estimates for the first time in four quarters, and the shares are roughly flat in 2026 after a 13% rise over the past month. The 20 analysts tracked by Yahoo Finance hold an average target near $107, above the November 20 close of about $77, with the BBP-418 FDA decision due by November 27.

CM. Every figure CIBC reports is in Canadian dollars, so screeners that print a CAD revenue line next to a USD market cap will look wrong by roughly 39%. Trailing revenue and EPS above add the July 2026 quarter to the prior three filed quarters; reported EPS in the July quarter was cut by ~C$0.26 of items, mainly Caribbean sale charges. After the stock slipped about 17% from its 52-week high near US$124.86, it trades around 14x trailing and 13x forward earnings, and the next print, fourth-quarter fiscal 2026, is scheduled for December 3, 2026, with consensus adjusted EPS near C$2.52 on about C$8.31 billion of revenue.

Headline figures (approximate, November 2026): BBIO shows revenue (ttm) ~$946M, revenue (q3 2026) ~$353M, up ~193% year over year, q3 2026 eps vs estimate ~-$0.42 vs ~-$0.56, net income (ttm) ~-$592M; CM shows revenue (ttm to jul 31, 2026) ~C$32.3B, latest quarter (q3 fy2026, ended jul 31, 2026) Revenue ~C$8,368M, +15% YoY; reported net income ~C$2,409M, +15%, eps Q3 adjusted ~C$2.73 vs ~C$2.52 consensus; reported ~C$2.47; TTM reported ~C$10.41, profitability and capital Adjusted ROE 16.8% (reported 15.2%), CET1 13.4%, NIM 1.63%, PCL ~C$564M.

The bottom line: BBIO vs CM

BBIO and CM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BBIO and CM exposure against your real portfolio. It is not an investment adviser.

Wondering how BBIO or CM fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about BridgeBio Pharma

Ask Walnut's AI anything about BBIO and see how it fits what you own.

FAQ

What is the difference between BBIO and CM?

+

BridgeBio Pharma (NASDAQ: BBIO) is a Palo Alto-based biopharmaceutical company focused on genetic diseases and genetically driven cancers. Canadian Imperial Bank of Commerce, founded in 1867 and run out of CIBC Square in Toronto, banks roughly 15 million personal, business, public-sector and institutional clients. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is BBIO or CM the better stock?

+

Neither is universally better. CM is the larger incumbent; BBIO is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, BBIO or CM?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both BBIO and CM?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of BBIO vs CM?

+

BBIO: The dominant risk is concentration: Attruby is BridgeBio's only approved commercial product, so near-term performance is highly dependent on a single therapy in a competitive market. Pfizer's entrenched tafamidis franchise and Alnylam's vutrisiran (Amvuttra) are well-funded rivals fighting for the same patients. Any FDA delay, rejection, request for more data, or narrower-than-expected label for BBP-418 (decision due by November 27, 2026), infigratinib, or encaleret would push out the diversification timeline. The company is still unprofitable, with a trailing net loss near $592 million and roughly $3.38 billion of debt, and although the third-quarter loss beat estimates, the three quarters before it came in wider than expected. Pricing pressure, slower diagnosis growth, or a valuation that still embeds heavy optimism (about 16 times trailing sales) could all weigh on the shares. CM: CIBC carries the heaviest relative exposure to Canadian residential mortgages of the country's large banks, and gross impaired loans reached ~C$3,967 million at April 30, 2026, up ~C$672 million from a year earlier, with the loan loss ratio at 0.38%. Renewal risk on mortgages written at much lower rates is a live issue for the Canadian consumer and lands on CIBC harder than on peers. Provisions for credit losses were ~C$564 million in the July quarter, and provisions on impaired loans rose in both Canadian segments and Capital Markets. Valuation is now part of the risk too, since the shares trade near ~2.0 times book after a roughly 26% twelve-month gain, at a bank that historically traded at a discount to Royal Bank and National Bank. US holders take a second exposure to the Canadian dollar on top of the equity, because earnings, book value and the dividend are all set in CAD. Legal matters remain open rather than dormant, including proposed class actions naming CIBC World Markets over alleged spoofing in Quantum BioPharma shares and a certified class action in Pope v. CIBC now under appeal, with the bank estimating reasonably possible losses above accruals of nil to ~C$0.4 billion.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BBIO or CM; figures are approximate and dated (as of November 2026). Verify current data before investing.